Valuation: Minerva Surgical, Inc.

Capitalization 10.39M 9.89M 9.33M 8.24M 14.72M 900M 16.33M 111M 41.14M 376M 38.94M 38.16M 1.58B P/E ratio 2021
-1.68x
P/E ratio 2022 -0.19x
Enterprise value 43.14M 41.07M 38.73M 34.21M 61.12M 3.74B 67.82M 461M 171M 1.56B 162M 158M 6.56B EV / Sales 2021
2.82x
EV / Sales 2022 0.78x
Free-Float
30.76%
Yield 2021 *
-
Yield 2022 -
More valuation ratios * Estimated data
Dynamic Chart
1 year
0.00
Extreme 0
0.72
3 years
0.00
Extreme 0
120.80
5 years
0.00
Extreme 0
207.40
10 years
0.00
Extreme 0
207.40
More quotes
Director TitleAgeSince
Chief Executive Officer 58 2023-01-01
Chief Tech/Sci/R&D Officer 59 2010-12-31
Chief Operating Officer 63 2020-12-31
Manager TitleAgeSince
Director/Board Member 59 2021-01-31
Director/Board Member 60 2021-05-31
Director/Board Member 52 2022-07-19
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
-.--%-.--% - - 8
-0.82%-1.59%+10.23%+53.80% 148B
-0.10%+2.40%-6.56%-14.97% 11.22B
+4.66%+0.08%+61.72%+184.76% 8.07B
+3.84%+5.90%-19.45%-39.09% 7.57B
-0.82%+1.90%-3.28%-17.48% 5.55B
+0.75%-.--%+4.61%+33.62% 3.63B
+0.41%-0.25%-25.82%-64.40% 2.49B
+0.55%-0.63%+21.77%-27.94% 1.95B
+2.62%+0.66%-17.47%-14.71% 1.94B
Average +1.08%-0.56%+2.86%+10.40% 19.05B
Weighted average by Cap. -0.28%-1.55%+9.11%+46.06%
See all sector performances

Financials

2021 2022
Net sales 52.1M 49.6M 46.78M 41.32M 73.82M 4.51B 81.92M 557M 206M 1.89B 195M 191M 7.92B 50.29M 47.88M 45.16M 39.88M 71.26M 4.36B 79.07M 538M 199M 1.82B 189M 185M 7.65B
Net income -21.46M -20.43M -19.27M -17.02M -30.41M -1.86B -33.75M -229M -85.01M -778M -80.46M -78.84M -3.26B -34.11M -32.47M -30.63M -27.05M -48.33M -2.96B -53.63M -365M -135M -1.24B -128M -125M -5.19B
Net Debt -1.33M -1.27M -1.2M -1.06M -1.89M -116M -2.1M -14.26M -5.28M -48.32M -5M -4.9M -203M 32.75M 31.18M 29.4M 25.97M 46.4M 2.84B 51.49M 350M 130M 1.19B 123M 120M 4.98B
More financial data * Estimated data
Logo Minerva Surgical, Inc.
Minerva Surgical, Inc. is a uterine health company. The Company is engaged in manufacturing and distribution of invasive gynecologic technologies. The Company is focused on improving women's health and quality of life by providing access to minimally invasive, technologically advanced, and innovative solutions for early detection, treatment, and management of uterine conditions. It delivers devices that treat the root causes of Abnormal Uterine Bleeding (AUB) in both the normal and irregular shaped uterus. The Company's products include Minerva ES Endometrial Ablation System (Minerva ES), Genesys HTA Endometrial Ablation System (Genesys HTA), Symphion Operative Hysteroscopy System (Symphion), Resectr Tissue Resection Device (Resectr), and Disposable Hysteroscope. Minerva ES is an endometrial ablation device that utilizes its PlasmaSense technology. Symphion System is designed to transform the way you see and remove uterine fibroids and polyps.
Employees
174
More about the company
Date Price Change Volume
25-02-12 - $ +-NaN% 1

Delayed Quote OTC Markets, December 31, 2024 at 11:14 am EST

More quotes

Quarterly revenue - Rate of surprise